{"id":3645,"date":"2017-07-24T14:43:23","date_gmt":"2017-07-24T12:43:23","guid":{"rendered":"http:\/\/www.thema-med.com\/?p=3645\/"},"modified":"2022-07-27T10:58:00","modified_gmt":"2022-07-27T08:58:00","slug":"usa-updated-post-market-surveillance-guideline-for-class-2-and-3-devices","status":"publish","type":"post","link":"https:\/\/www.thema-med.com\/en\/2017\/07\/24\/usa-updated-post-market-surveillance-guideline-for-class-2-and-3-devices\/","title":{"rendered":"USA: updated the post-market surveillance guideline for class 2 and class 3 devices"},"content":{"rendered":"

On May 16, 2016 the FDA published the updated guideline \u201cPostmarket Surveillance under section 522 of the Food, Drug and Cosmetic Act\u201d.
\nThis guidance is applicable when FDA officially orders to the class 2 and class 3 medical device manufacturers to execute post-market surveillance and reporting activities.
\nSome of the main articles of this new version are listed here below:<\/p>\n

    \n
  1. After the approval of the registered device, the FDA can order to perform post-market surveillance at any time. This order must be executed within 15 months from the emission.<\/li>\n
  2. Manufacturers can require changes to the surveillance program approved by FDA.<\/li>\n
  3. Once evaluated, FDA can send many types of \u201cdecision letters\u201d in order to approve the changes<\/li>\n
  4. FDA can disclose data and analysis report in order to protect the patient.<\/li>\n<\/ol>\n

     <\/p>\n

    For further information:<\/p>\n

    http:\/\/www.fda.gov\/ucm\/groups\/fdagov-public\/@fdagov-meddev-gen\/documents\/document\/ucm268141.pdf?source=govdelivery&utm_medium=email&utm_source=govdelivery<\/a><\/p>\n

     <\/p>\n","protected":false},"excerpt":{"rendered":"

    On May 16, 2016 the FDA published the updated guideline \u201cPostmarket Surveillance under section 522 of the Food, Drug and Cosmetic […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[2],"tags":[1568],"class_list":["post-3645","post","type-post","status-publish","format-standard","hentry","category-news-en","tag-usa-topic"],"acf":[],"yoast_head":"\nUSA: updated post-market surveillance guideline for class 2 and 3 devices<\/title>\n<meta name=\"description\" content=\"On May 16, 2016 the FDA published the updated guideline \u201cPostmarket Surveillance under section 522 of the Food, Drug and Cosmetic Act\u201d. This guidance...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.thema-med.com\/en\/2017\/07\/24\/usa-updated-post-market-surveillance-guideline-for-class-2-and-3-devices\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"USA: updated post-market surveillance guideline for class 2 and 3 devices\" \/>\n<meta property=\"og:description\" content=\"On May 16, 2016 the FDA published the updated guideline \u201cPostmarket Surveillance under section 522 of the Food, Drug and Cosmetic Act\u201d. This guidance...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.thema-med.com\/en\/2017\/07\/24\/usa-updated-post-market-surveillance-guideline-for-class-2-and-3-devices\/\" \/>\n<meta property=\"og:site_name\" content=\"Thema Med\" \/>\n<meta property=\"article:published_time\" content=\"2017-07-24T12:43:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-07-27T08:58:00+00:00\" \/>\n<meta name=\"author\" content=\"redazione\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"redazione\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.thema-med.com\/en\/2017\/07\/24\/usa-updated-post-market-surveillance-guideline-for-class-2-and-3-devices\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.thema-med.com\/en\/2017\/07\/24\/usa-updated-post-market-surveillance-guideline-for-class-2-and-3-devices\/\"},\"author\":{\"name\":\"redazione\",\"@id\":\"https:\/\/www.thema-med.com\/en\/#\/schema\/person\/8cb6614629bd6664e6f294690d35677e\"},\"headline\":\"USA: updated the post-market surveillance guideline for class 2 and class 3 devices\",\"datePublished\":\"2017-07-24T12:43:23+00:00\",\"dateModified\":\"2022-07-27T08:58:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.thema-med.com\/en\/2017\/07\/24\/usa-updated-post-market-surveillance-guideline-for-class-2-and-3-devices\/\"},\"wordCount\":161,\"publisher\":{\"@id\":\"https:\/\/www.thema-med.com\/en\/#organization\"},\"keywords\":[\"US Topic\"],\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.thema-med.com\/en\/2017\/07\/24\/usa-updated-post-market-surveillance-guideline-for-class-2-and-3-devices\/\",\"url\":\"https:\/\/www.thema-med.com\/en\/2017\/07\/24\/usa-updated-post-market-surveillance-guideline-for-class-2-and-3-devices\/\",\"name\":\"USA: updated post-market surveillance guideline for class 2 and 3 devices\",\"isPartOf\":{\"@id\":\"https:\/\/www.thema-med.com\/en\/#website\"},\"datePublished\":\"2017-07-24T12:43:23+00:00\",\"dateModified\":\"2022-07-27T08:58:00+00:00\",\"description\":\"On May 16, 2016 the FDA published the updated guideline \u201cPostmarket Surveillance under section 522 of the Food, Drug and Cosmetic Act\u201d. This guidance...\",\"breadcrumb\":{\"@id\":\"https:\/\/www.thema-med.com\/en\/2017\/07\/24\/usa-updated-post-market-surveillance-guideline-for-class-2-and-3-devices\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.thema-med.com\/en\/2017\/07\/24\/usa-updated-post-market-surveillance-guideline-for-class-2-and-3-devices\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.thema-med.com\/en\/2017\/07\/24\/usa-updated-post-market-surveillance-guideline-for-class-2-and-3-devices\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.thema-med.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"USA: updated the post-market surveillance guideline for class 2 and class 3 devices\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.thema-med.com\/en\/#website\",\"url\":\"https:\/\/www.thema-med.com\/en\/\",\"name\":\"Thema Med\",\"description\":\"Quality and Regulatory Affairs for Medical Devices\",\"publisher\":{\"@id\":\"https:\/\/www.thema-med.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.thema-med.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Organization\",\"Place\"],\"@id\":\"https:\/\/www.thema-med.com\/en\/#organization\",\"name\":\"Thema\",\"alternateName\":\"Thema\",\"url\":\"https:\/\/www.thema-med.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.thema-med.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.thema-med.com\/wp-content\/uploads\/2022\/11\/logo-Themasrl-COLOR-hires-2440.png\",\"contentUrl\":\"https:\/\/www.thema-med.com\/wp-content\/uploads\/2022\/11\/logo-Themasrl-COLOR-hires-2440.png\",\"width\":2440,\"height\":2851,\"caption\":\"Thema\"},\"image\":{\"@id\":\"https:\/\/www.thema-med.com\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.linkedin.com\/company\/thema-s-r-l-\/\"],\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.thema-med.com\/en\/2017\/07\/24\/usa-updated-post-market-surveillance-guideline-for-class-2-and-3-devices\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.thema-med.com\/en\/#\/schema\/person\/8cb6614629bd6664e6f294690d35677e\",\"name\":\"redazione\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.thema-med.com\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/b256f44c95829224dda80aff96bb893da058966fe2e8b7b58ece2b0d74ffa04d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/b256f44c95829224dda80aff96bb893da058966fe2e8b7b58ece2b0d74ffa04d?s=96&d=mm&r=g\",\"caption\":\"redazione\"},\"sameAs\":[\"http:\/\/www.thema-med.eu\"],\"url\":\"https:\/\/www.thema-med.com\/en\/author\/emanuele\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"USA: updated post-market surveillance guideline for class 2 and 3 devices","description":"On May 16, 2016 the FDA published the updated guideline \u201cPostmarket Surveillance under section 522 of the Food, Drug and Cosmetic Act\u201d. This guidance...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.thema-med.com\/en\/2017\/07\/24\/usa-updated-post-market-surveillance-guideline-for-class-2-and-3-devices\/","og_locale":"en_US","og_type":"article","og_title":"USA: updated post-market surveillance guideline for class 2 and 3 devices","og_description":"On May 16, 2016 the FDA published the updated guideline \u201cPostmarket Surveillance under section 522 of the Food, Drug and Cosmetic Act\u201d. This guidance...","og_url":"https:\/\/www.thema-med.com\/en\/2017\/07\/24\/usa-updated-post-market-surveillance-guideline-for-class-2-and-3-devices\/","og_site_name":"Thema Med","article_published_time":"2017-07-24T12:43:23+00:00","article_modified_time":"2022-07-27T08:58:00+00:00","author":"redazione","twitter_card":"summary_large_image","twitter_misc":{"Written by":"redazione","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.thema-med.com\/en\/2017\/07\/24\/usa-updated-post-market-surveillance-guideline-for-class-2-and-3-devices\/#article","isPartOf":{"@id":"https:\/\/www.thema-med.com\/en\/2017\/07\/24\/usa-updated-post-market-surveillance-guideline-for-class-2-and-3-devices\/"},"author":{"name":"redazione","@id":"https:\/\/www.thema-med.com\/en\/#\/schema\/person\/8cb6614629bd6664e6f294690d35677e"},"headline":"USA: updated the post-market surveillance guideline for class 2 and class 3 devices","datePublished":"2017-07-24T12:43:23+00:00","dateModified":"2022-07-27T08:58:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.thema-med.com\/en\/2017\/07\/24\/usa-updated-post-market-surveillance-guideline-for-class-2-and-3-devices\/"},"wordCount":161,"publisher":{"@id":"https:\/\/www.thema-med.com\/en\/#organization"},"keywords":["US Topic"],"articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.thema-med.com\/en\/2017\/07\/24\/usa-updated-post-market-surveillance-guideline-for-class-2-and-3-devices\/","url":"https:\/\/www.thema-med.com\/en\/2017\/07\/24\/usa-updated-post-market-surveillance-guideline-for-class-2-and-3-devices\/","name":"USA: updated post-market surveillance guideline for class 2 and 3 devices","isPartOf":{"@id":"https:\/\/www.thema-med.com\/en\/#website"},"datePublished":"2017-07-24T12:43:23+00:00","dateModified":"2022-07-27T08:58:00+00:00","description":"On May 16, 2016 the FDA published the updated guideline \u201cPostmarket Surveillance under section 522 of the Food, Drug and Cosmetic Act\u201d. This guidance...","breadcrumb":{"@id":"https:\/\/www.thema-med.com\/en\/2017\/07\/24\/usa-updated-post-market-surveillance-guideline-for-class-2-and-3-devices\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.thema-med.com\/en\/2017\/07\/24\/usa-updated-post-market-surveillance-guideline-for-class-2-and-3-devices\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.thema-med.com\/en\/2017\/07\/24\/usa-updated-post-market-surveillance-guideline-for-class-2-and-3-devices\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.thema-med.com\/en\/"},{"@type":"ListItem","position":2,"name":"USA: updated the post-market surveillance guideline for class 2 and class 3 devices"}]},{"@type":"WebSite","@id":"https:\/\/www.thema-med.com\/en\/#website","url":"https:\/\/www.thema-med.com\/en\/","name":"Thema Med","description":"Quality and Regulatory Affairs for Medical Devices","publisher":{"@id":"https:\/\/www.thema-med.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.thema-med.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Organization","Place"],"@id":"https:\/\/www.thema-med.com\/en\/#organization","name":"Thema","alternateName":"Thema","url":"https:\/\/www.thema-med.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.thema-med.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.thema-med.com\/wp-content\/uploads\/2022\/11\/logo-Themasrl-COLOR-hires-2440.png","contentUrl":"https:\/\/www.thema-med.com\/wp-content\/uploads\/2022\/11\/logo-Themasrl-COLOR-hires-2440.png","width":2440,"height":2851,"caption":"Thema"},"image":{"@id":"https:\/\/www.thema-med.com\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/thema-s-r-l-\/"],"mainEntityOfPage":{"@id":"https:\/\/www.thema-med.com\/en\/2017\/07\/24\/usa-updated-post-market-surveillance-guideline-for-class-2-and-3-devices\/"}},{"@type":"Person","@id":"https:\/\/www.thema-med.com\/en\/#\/schema\/person\/8cb6614629bd6664e6f294690d35677e","name":"redazione","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.thema-med.com\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/b256f44c95829224dda80aff96bb893da058966fe2e8b7b58ece2b0d74ffa04d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b256f44c95829224dda80aff96bb893da058966fe2e8b7b58ece2b0d74ffa04d?s=96&d=mm&r=g","caption":"redazione"},"sameAs":["http:\/\/www.thema-med.eu"],"url":"https:\/\/www.thema-med.com\/en\/author\/emanuele\/"}]}},"_links":{"self":[{"href":"https:\/\/www.thema-med.com\/en\/wp-json\/wp\/v2\/posts\/3645","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.thema-med.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.thema-med.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.thema-med.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.thema-med.com\/en\/wp-json\/wp\/v2\/comments?post=3645"}],"version-history":[{"count":1,"href":"https:\/\/www.thema-med.com\/en\/wp-json\/wp\/v2\/posts\/3645\/revisions"}],"predecessor-version":[{"id":22183,"href":"https:\/\/www.thema-med.com\/en\/wp-json\/wp\/v2\/posts\/3645\/revisions\/22183"}],"wp:attachment":[{"href":"https:\/\/www.thema-med.com\/en\/wp-json\/wp\/v2\/media?parent=3645"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.thema-med.com\/en\/wp-json\/wp\/v2\/categories?post=3645"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.thema-med.com\/en\/wp-json\/wp\/v2\/tags?post=3645"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}